Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Boston Scientific underperformed the broader market, though analysts remain optimistic, citing strong earnings execution, innovation, and meaningful upside from current levels.
Analyst fair value for Boston Scientific has shifted from US$75.00 to US$72.25, pointing to a modest reset in price targets. This change lines up with recent research that lowers expectations for Watchman and electrophysiology while still recognizing strengths across the broader portfolio and generally positive ratings. As you read on, you will see how these moving targets, both bullish and bearish, shape the evolving Boston Scientific story and what to watch next. Stay updated as the Fair...
Boston Scientific recently reported its second-quarter 2026 results, showing sales of US$5,442 million and net income of US$907 million, alongside issuing a recall of its Rapid Refill Continuous Injection System and initiating a multi-year global restructuring plan aimed at cost efficiencies. While the company raised full-year 2026 net sales growth expectations to approximately 5.5%–6.5%, it also outlined a restructuring program costing up to US$800 million and targeting around US$500...
Moby summary of Boston Scientific Corporation's Q2 2026 earnings call
Boston Scientific (NYSE:BSX) reported second-quarter 2026 revenue growth at the high end of its guidance range and adjusted earnings per share above expectations, but lowered its full-year outlook as it faces slowing demand in its WATCHMAN left atrial appendage closure business and increased competi
Boston Scientific Corp (BSX) reports a robust Q2 with 7% organic sales growth and a 15% increase in adjusted EPS, despite challenges in some segments.
Boston Scientific Corp (NYSE:BSX, XETRA:BSX) reported second quarter results that exceeded analyst expectations for revenue and adjusted earnings, while raising its full-year sales outlook. The medical device company posted adjusted earnings per share of $0.86, ahead of the $0.83 consensus...
Boston's tempered 2026 outlook is likely due in part to its recently announced plans to initiate a global restructuring programme.
Boston Scientific (BSX) lowered its full-year guidance below Wall Street's estimates on Wednesday, c
Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The medical device maker topped second-quarter expectations but now sees full-year adjusted EPS of $3.28 to $3.32, down from a prior range of $3.34 to $3.41
BSX beats Q2 earnings and revenue estimates as cardiovascular growth, strong APAC and LACA sales, and margin expansion lift shares in pre-market.
Boston Scientific (NYSE:BSX) shares rose more than 3% in pre-market trading on Wednesday after the medical device manufacturer reported second-quarter earnings and revenue that exceeded Wall Street expectations, supported by broad-based growth across its business. The company reported earnings of $0.
Boston Scientific (BSX) delivered earnings and revenue surprises of +3.61% and +1.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Boston Scientific logged higher second-quarter results and cut its full-year outlook as it begins a new restructuring plan announced earlier this week.
July 29 (Reuters) - Medical device maker Boston Scientific on Wednesday lowered its annual profit forecast, citing pressure on its Watchman heart device business.
Investing.com -- Shares in Boston Scientific rose over 3% in premarket trading Wednesday after the medical device maker reported second-quarter earnings and revenue that topped Wall Street estimates.
Medical device company Boston Scientific (NYSE:BSX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 7.5% year on year to $5.44 billion. On the other hand, next quarter’s revenue guidance of $5.27 billion was less impressive, coming in 2.2% below analysts’ estimates. Its non-GAAP profit of $0.86 per share was 3.8% above analysts’ consensus estimates.
Boston expects its restructuring plan to cost between $700m and $800m and be completed by the end of 2029.
Wall Street analysts are busy reshuffling their ratings ahead of the Fed meeting, with surprise double-upgrades, dramatic target cuts, and fresh initiations spanning surgical robots to cybersecurity. Find out which names made the biggest moves today.
The plan involves transferring production lines and cutting jobs, following a slowdown in two of the company’s key product lines.
Medical device company Boston Scientific (NYSE:BSX) will be reporting earnings this Wednesday morning. Here’s what to expect.
J&J's MedTech growth slowed down in Q2 as Cardiovascular lagged, but new product launches and stronger Vision, Surgery and Orthopedics may lift H2 sales.
Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
Device makers with cash flow yields of 5% to 6% now trade at a 20% to 30% discount to the S&P 500 index.
Device makers with cash flow yields of 5% to 6% now trade at a 20% to 30% discount to the S&P 500 index.
Boston Scientific (NYSE:BSX) has enrolled the first patients in the global FARADIGM trial. The study evaluates the Faraflex pulsed field ablation device for the treatment of atrial fibrillation. This milestone marks the formal start of large scale clinical testing for the Faraflex system. Boston Scientific is a major player in cardiac rhythm and electrophysiology devices, and the FARADIGM trial adds another clinical program to that portfolio. Atrial fibrillation treatments have been an area...
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
